FMP

FMP

Enter

PACB - Pacific Biosciences ...

photo-url-https://images.financialmodelingprep.com/symbol/PACB.png

Pacific Biosciences of California, Inc.

PACB

NASDAQ

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

1.36 USD

-0.02 (-1.47%)

PACB Financial Statements

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Total Revenue

39.22M

39.97M

36.01M

38.81M

Cost of Revenue

29.17M

29.96M

30.07M

34.38M

Gross Profit

10.06M

10M

5.94M

4.43M

Operating Expenses

132.72M

69.26M

68.3M

85.86M

Research and Development

27.47M

25.52M

38.48M

43.45M

Selling, General & Administrative Expenses

41.64M

43.75M

45.88M

42.41M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

0

0

0

0

Other Expenses

63.61M

0

67.35M

6.76M

Operating Income

-122.66M

-59.26M

-145.77M

-81.43M

Total Other Income/Expenses Net

125.35M

-1.47M

-27.55M

3.18M

Income Before Tax

2.69M

-60.73M

-173.32M

-78.18M

Income Tax

316k

0

0

11.97M

Net Income

2.37M

-60.73M

-173.32M

-78.18M

Basic EPS

0.01

-0.22

-0.64

-0.29

EPS Diluted

0.01

-0.22

-0.64

-0.29

Basic Average Shares

283M

272.92M

272.38M

269.58M

Diluted Average Shares

306.89M

272.92M

272.38M

269.58M

EBITDA

-122.66M

-41.09M

-155.49M

-62.59M

Retained Earning Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Retained Earnings (Previous Year)

-2.15B

-2.09B

-1.92B

-1.84B

Net Income

2.37M

-60.73M

-173.32M

-78.18M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

0

-2.15B

-2.09B

-1.92B

Other Distributions

2.15B

-60.73M

-173.32M

-78.18M

PPE Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Gross PPE

46.6M

49.3M

57.3M

67.96M

Annual Depreciation

10.95M

16.1M

14.29M

12.01M

Capital Expenditure

-1.62M

787k

-1.48M

-3.88M

Net PPE

37.26M

32.41M

44.49M

59.83M

Intangible and Goodwill Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Acquisitions and Adjustments

-55.1M

0

-93.2M

0

Goodwill (Previous Year)

369.06M

369.06M

462.26M

462.26M

Goodwill

313.96M

369.06M

369.06M

462.26M

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep